Decrease in Mortality in severe community-acquired pneumococcal pneumonia: Impact of improving antibiotic strategies (2000-2013)

Chest

Volumn 146, Issue 1, 2014, Pages 22-31

  Gattarello, Simone ^a   Borgatta, Bárbara ^a   Solé Violán, Jordi ^b,g,h,i   Vallés, Jordi ^c,g,h   Vidaur, Loreto ^d,g,h   Zaragoza, Rafael ^e   Torres, Antoni ^f,g,h   Rello, Jordi ^a,g,h  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Dr Negrin University Hospital Las Palmas de Gran Canaria Critical Care Center   (Japan)

^d HOSPITAL DE SABADELL   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ Virgen de Las Nieves H   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; EUROPE; FEMALE; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHOCK; STREPTOCOCCUS PNEUMONIA; SURVIVAL;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84903825939     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1531     Document Type: Article

References (51)

1. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Dis eases Society of America; American Thoracic Society. Infec tious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 (suppl 2): S27 - S72.
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of communityacquired pneumonia among adults in Europe. Thorax. 2012; 67 (1): 71-79.
3. Kang CI, Song JH, Kim SH, et al. Risk factors and pathogenic signifi cance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013; 66 (1): 34-40.
4. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002; 166 (5): 717-723.
5. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde- Zwirble WT. Hospitalized communityacquired pneu monia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002; 165 (6): 766-772.
6. Menéndez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are infl uenced by microorganisms in community-acquired pneumonia. Chest. 2012; 141 (6): 1537-1545.
7. Crisafulli E, Menéndez R, Huerta A, et al. Systemic infl ammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest. 2013; 143 (4): 1009-1017.
8. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. Th e impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with communityacquired pneumonia. BMC Pulm Med. 2005; 5: 12-18.
9. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Com parison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005; 60 (8): 672-678.
10. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneu monia: systematic review of randomized controlled trials. Arch Intern Med. 2005; 165 (17): 1992-2000.
11. Bodí M, Rodríguez A, Solé-Violán J, et al; Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005; 41 (12): 1709-1716.
12. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003; 37 (11): 1405-1433.
13. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996; 275 (2): 134-141.
14. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of communityacquired pneumonia in the adult population of 4 municipalities in eastern Finland. C lin Infect Dis. 2001; 32 (8): 1141-1154.
15. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993; 137 (9): 977-988.
16. Froes F. Community-acquired pneumonia in adults in mainland Portugal: incidence and mortality in hospital inpatients between 1998 and 2000 [in Portugese]. Rev Port Pneumol. 2003; 9 (3): 187-194.
17. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008; 14 (5): 727-733.
18. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013; 41 (5): 1167-1174.
19. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med. 2012; 40 (3): 754-761.
20. Kumar G, Kumar N, Taneja A, et al; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest. 2011; 140 (5): 1223-1231.
21. Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest. 1993; 103 (1): 232-235.
22. Lim WS, van der Eerden MM, Laing R, et al. Defi ning community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58 (5): 377-382.
23. Yoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality. Intern Med. 2005; 44 (7): 710-716.
24. Sirvent JM, Carmen de la Torre M, Lorencio C, et al. Predic tive factors of mortality in severe community-acquired pneu monia: a model with data on the fi rst 24h of ICU admission. Med Intensiva. 2013; 37 (5): 308-315.
25. Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract. 2013; 67 (5): 477-487.
26. Ishiguro T, Takayanagi N, Yamaguchi S, et al. Etiology and factors contributing to the severity and mortality of communityacquired pneumonia. Intern Med. 2013; 52 (3): 317-324.
27. World Health Organization. Th e World Health Report 2004 - Changing History. Geneva, Switzerland; World Health Orga nization; 2004.
28. World Health Organization. The World Health Report 1995bridging the gaps. World Health Forum. 1995; 16 (4): 377-385.
29. Hughes JM. Emerging infectious diseases: a CDC perspective. Emerg Infect Dis. 2001; 7 (suppl 3): 494-496.
30. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest. 1999; 115 (suppl 3): 24S - 27S.
31. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Defi nitions Conference. Crit Care Med. 2003; 31 (4): 1250-1256.
32. Vallés J, Palomar M, Alvárez-Lerma F, et al; GTEI/SEMICYUC Working Group on Bacteremia. Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med. 2013; 41 (1): 76-83.
33. Ferrer M, Menendez R, Amaro R, Torres A. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. Clin Chest Med. 2011; 32 (3): 491-505.
34. Menéndez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J. 2012; 39 (1): 156-162.
35. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including Th e Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39 (2): 165-228.
36. Th e Acute Respiratory Distress Syndrome Network. Ventila tion with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342 (18): 1301-1308.
37. Esquinas Rodriguez AM, Papadakos PJ, Carron M, Cosentini R, Chiumello D. Clinical review: helmet and non-invasive mechanical ventilation in critically ill patients. Crit Care. 2013; 17 (2): 223.
38. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010; 38 (4): 1045-1053.
39. Nobre V, Sarasin FP, Pugin J. Prompt antibiotic administration and goal-directed hemodynamic support in patients with severe sepsis and septic shock. Curr Opin Crit Care. 2007; 13 (5): 586-591.
40. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of eff ective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34 (6): 1589-1596.
41. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest. 2006; 130 (1): 11-15.
42. Bordon J, Aliberti S, Duvvuri P, et al. Early administration of the fi rst antimicrobials should be considered a marker of optimal care of patients with communityacquired pneu monia rather than a predictor of outcomes. Int J Infect Dis. 2013; 17 (5): e293 - e298.
43. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneu monia. Arch Intern Med. 2001; 161 (15): 1837-1842.
44. Baddour LM, Yu VL, Klugman KP, et al; International Pneu mococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170 (4): 440-444.
45. Luján M, Gallego M, Rello J. Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med. 2006; 32 (7): 971-980.
46. Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax. 2013; 68 (6): 571-579.
47. Burgos J, Luján M, Larrosa MN, et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J. 2014; 43 (2): 545-553.
48. Burgos J, Lujan M, Falcó V, et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis. 2011; 53 (3): 254-261.
49. Luján M, Gallego M, Belmonte Y, et al. Infl uence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J. 2010; 36 (5): 1073-1079.
50. Griffi n MR, Zhu Y, Moore MRUS, Whitney CG, Grijalva CG. U. S. hospitalizations for pneumonia aft er a decade of pneumococcal vaccination. N Engl J Med. 2013; 369 (2): 155-163.
51. Rello J, Lisboa T, Lujan M, et al; DNANeumococo Study Group. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009; 136 (3): 832-840.